Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 9 NOVEMBER 2026

The Board announces that the EGM Resolution as set out in the EGM Notice were duly passed by the Shareholders by way of poll at the EGM held on 9 November 2026.

References are made to the circular (the "**Circular**") and notice of extraordinary general meeting (the "**EGM Notice**") issued by China NT Pharma Group Company Limited (the "**Company**") dated 21 October 2026 in connection with the extraordinary general meeting (the "**EGM**"). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EGM

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce the poll results of the EGM held at Unit 2102, 21/F, Shun Tak Centre – West Tower, 168–200 Connaught Road Central, Hong Kong on 9 November 2026 at 11:00 a.m.

The EGM was presided over by Ms. Chin Yu, a non-executive Director. All Directors attended the EGM in person or by electronic means.

As at the date of the EGM, there were a total of 1,796,563,586 Shares in issue, being the total number of Shares entitling the Shareholders to attend and vote on the resolution proposed at the EGM (the "**Resolution**"). There were no Shares entitling the Shareholders to attend the EGM and abstain from voting in favour of the Resolution as set out in Rule 13.40 of the Listing Rules. No Shareholders were required under the Listing Rules to abstain from voting on or to vote only against the Resolution at the EGM. No parties had stated his/her/its intention in the Circular their attention to vote against or to abstain from voting on the ordinary resolution at the EGM.

The Hong Kong branch share registrar and transfer office of the Company, Tricor Investor Services Limited, was appointed as the scrutineer for vote taking at the EGM.

The Board is pleased to announce that all the resolution as set out in the EGM Notice have been duly passed by the Shareholders by way of poll at the EGM and the details of poll results are as follows:

Ordinary Resolution [(1)]		**No. of Votes (%)**	
		For	**Against**
1.	To consider and approve the appointment of HLB Hodgson Impey Cheng Limited as the auditor of the Company with effect from the passing of this resolution, to hold office until the conclusion of the next annual general meeting of the Company, and to authorise the board of directors of the Company to determine their remuneration.	523,036,451 (100.00%)	0 (0.00%)

Note:

(1) The full text of the resolution is set out in EGM Notice.

As more than 50% of the valid votes were cast in favour of the Resolution, it was duly passed as an ordinary resolution of the Company. Accordingly, HLB Hodgson Impey Cheng Limited will be appointed as the auditor of the Company.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 9 November 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.